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Abstract
Objective: Plasma apolipoprotein (apo)D, a ubiquitously expressed protein that
binds small hydrophobic ligands, is found mainly on HDL particles. According to
studies of human genetics and lipid disorders, plasma apoD levels positively
correlate with HDL-cholesterol and apoAI levels. Thus, we tested the hypothesis
that apoD was a regulator of HDL metabolism.
Methods & Results:We compared the plasma lipid and lipoprotein profiles of wild-
type (WT) C57BL/6 mice with apoD2/2 mice on a C57BL/6 background after
receiving a high fat-high cholesterol diet for 12 weeks. ApoD2/2 mice had higher
HDL-cholesterol levels (61¡13-apoD2/2 vs. 52¡10-WT-males; 37¡11-apoD2/2
vs. 22¡2 WT-female) than WT mice with sex-specific changes in total plasma
levels of cholesterol and other lipids. Compared to WT, the HDL of apoD2/2 mice
showed an increase in large, lipid-rich HDL particles and according to size various
quantities and sizes of LDL particles. Plasma levels of lecithin:cholesterol
acyltransferase in the control and apoD2/2 mice were not different, however,
plasma phospholipid transfer protein activity was modestly elevated (+10%) only in
male apoD2/2 mice. An in vivo HDL metabolism experiment with isolated
Western-fed apoD2/2 HDL particles showed that female apoD2/2 mice had a
36% decrease in the fractional catabolic rate of HDL cholesteryl ester. Hepatic SR-
BI and LDLR protein levels were significantly decreased; accordingly, LDL-
cholesterol and apoB levels were increased in female mice.
Conclusion: In the context of a high fat-high cholesterol diet, apoD deficiency in
female mice is associated with increases in both plasma HDL and LDL-cholesterol
levels, reflecting changes in expression of SR-BI and LDL receptors, which may
impact diet-induced atherosclerosis.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death in Western countries.
Plasma low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein
(HDL)-C levels correlate positively and negatively with CVD risk respectively
[1, 2]. Although statins reduce LDL-C and with it the incidence of CVD, new
therapeutic options are needed to raise plasma HDL-C in ways that are
atheroprotective. CETP-inhibitors raise circulating plasma HDL-C levels, but to
date none have prevented CVD [3]. Thus, the mechanisms by which HDL-C levels
are increased are likely to be more relevant to atheroprotection than the actual
HDL-C-raising itself [4]. The surface of HDL particles is approximately 85%
protein and the HDL proteome is heterogeneous [5]. HDL-proteins occur as
specific clusters in HDL subclasses, each exerting distinct biological functions–
including regulation of cholesterol efflux, and anti-inflammatory, anti-oxidative,
anti-thrombotic, and vasodilatory activities [6, 7]. Consequently, investigating the
biological effects of HDL-associated proteins on the function of this lipoprotein is
a key to understanding how HDL reduces CVD risk.
Apolipoprotein D (ApoD) is a 29-kDa glycoprotein associated mainly with
plasma HDL and to a lesser extent with LDL and very low-density lipoproteins
(VLDL) [8, 9]. The impact of apoD on lipid metabolism was partially clarified by
recent studies revealing that apoD regulates triglyceride metabolism. Hepatic
over-expression of mouse apoD reduced plasma triglyceride levels by increasing
lipoprotein lipase (LPL) activity and the catabolism of triglyceride-rich particles
[10]. Moreover, ApoD deficiency in mice is associated with reduced adipose
tissue-LPL levels and hypertriglyceridemia [11]. Although these observations
indicate that apoD regulates triglyceride metabolism, its role in the regulation of
HDL, its major carrier, is unknown.
Human apoD levels are reduced in hypocholesterolemic diseases that result
from deficiencies in proteins that modulate HDL-C levels, including Tangier
disease and familial lecithin-cholesterol acytransferase (LCAT) deficiency. Both
diseases are associated with lower apolipoproteins levels, an effect that was most
profound for apoD [12]. In a study of single nucleotide polymorphisms in the
human apoD gene of African Blacks, the Phe36Val SNP was associated with
increased HDL3-C and apoAI concentrations in females [13]. Another study
showed a strong positive correlation between apoD and apoAI levels, and HDL
lipid content (cholesterol and phospholipids) in healthy male subjects [14]. The
association between HDL and apoD may be linked to the biological activities of
HDL-associated remodeling enzymes, such as LCAT, phospholipid transfer
protein (PLTP), and paroxonases (PON). ApoD complexes with LCAT, and the
presence of apoD in proteoliposome particles composed of either apoAI or CI
stimulates the esterification activity of LCAT [15]. PLTP, which transfers
phospholipids among lipoproteins and modulates HDL particle size, forms a
complex composed of six apolipoproteins including apoD [16]. A human
proteomics study revealed that apoD is preferentially found in the smaller, denser
HDL3 subpopulation and is modestly positively correlated with the levels of
Apolipoprotein D and HDL
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PON1 and 3, proteins localized to small HDL3 [6]. The functional relationships
between apoD and HDL-associated enzymes, PON and PLTP, are unknown.
Collectively, however, these data suggest that apoD may regulate both HDL-C
levels and its functionality, although no studies have determined the mechanism
by which apoD influences plasma HDL-cholesterol. Since apoD is often up-
regulated under stress conditions or disease states, mice were fed an atherogenic
Western diet [8, 17, 18]. We tested the hypothesis that apoD affects circulating
plasma HDL-cholesterol levels by altering the lipid and protein content of HDL
and the catalytic activities of associated enzymes.
Materials and Methods
Mice
In-house 6–8 week old-aged matched male and female C57BL-6 and apoD2/2
mice were fed a Western Diet (Harlan-TD88137) for 12 weeks. Mice had ad-
libitum access to water. Animals were weighed and bled monthly after an
overnight fast. At time of sacrifice, mice were fasted overnight and anesthetized
with a ketamine/xylazine cocktail. Plasma and serum were collected via the retro-
orbital plexus. Plasma, sera, and liver were stored at 280 C˚ until further use. The
City College of New York Institutional Animal Care and Use Committee
approved all procedures.
Fast Protein Liquid Chromatography (FPLC)-size exclusion
analysis of pooled plasma samples
Pooled plasma (,150 ml) from each genotype (n54–6) was injected onto
Superose HR6 10/300 GL FPLC column (GE Healthcare). Lipoproteins were
eluted with 24 mL of elution buffer [0.15 M NaCl, 1 mM EDTA, 0.2% w/v of
sodium azide in 1X phosphate saline buffer (PBS)] and 0.5 mL fractions were
collected at a flow rate of 0.5 mL/min.
Plasma and Serum lipid analyses
Total cholesterol, free cholesterol, triglycerides, non-esterified fatty acids, and
phospholipids levels were measured in plasma or sera and FPLC samples
according to manufacturer instructions from Wako Chemicals or Infinity
Triglycerides. The total cholesterol levels in FPLC fractions were measured with
2X Cholesterol E buffer. Plasma HDL-cholesterol measurements were determine
after precipitation of apoB-containing lipoproteins. Briefly, plasma samples were
mixed with equal volumes of dextran sulfate (20 g/L) and magnesium chloride
(1 M) solution pH 7.0 and incubated for 10 minutes at room temperature
followed by centrifugation for 30 minutes at 4 C˚. The supernatant was measured
for cholesterol with the Cholesterol E kit (Wako).
Apolipoprotein D and HDL
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SDS-PAGE and Western Blotting
FPLC HDL fractions (25 mL), plasma (1 mL), or liver extract (25–50 mg) were
reduced with b-mercaptoethanol/Laemmli buffer, separated on 4–20% mini
Protean TGX gels (Bio-Rad), transferred to a PVDF membrane, and probed with
primary antibodies for mouse apoAI (Abcam-ab20453), mouse apoD (Santa
Cruz-sc34763), SR-BI (Novus Biologicals-NB400-104), LDLR (BioVision-3839-
100), and b-actin (Thermo Scientific-MA-91399). Proteins were detected with
ECL reagent (Promega) and the pixel intensities of bands were quantified by the
Image J program (NIH). For total protein analysis, 10–20 mg of total protein was
loaded on 4–20% mini TGX gel and gel stained with SimplyBlue SafeStain
(Invitrogen) to detect apolipoproteins’ levels in pooled FPLC fractions.
Plasma activities of LCAT and PLTP
Plasma LCAT and PLTP activities were measured with the Roar Biomedicals Kits
per vendor instructions.
Ion mobility of plasma lipoproteins
The lipoprotein concentrations and particle size from pooled plasma (100 mL)
were determined by gas-phase differential electrophoretic mobility method as
previously described [19].
Liver lipids measurement and relative mRNA expression
Livers (50 mg) from C57BL/6 and apoD2/2mice were homogenized in PBS with
a bullet blender for 5 minutes at 4 C˚ with zirconium oxide beads (ZrOB05 and
ZrOB10-Next Advance). The homogenate was collected and diluted after
centrifugation at 10,000 rpm and 4 C˚. An aliquot of homogenate was solubilized
with an equal volume of 0.25% or 1% deoxycholate to measure cholesterol and
triglyceride levels, respectively. Samples were incubated for 5 minutes at 37 C˚.
Infinity Cholesterol or Triglycerides liquid stable reagents (ThermoScientific)
were added to samples and glycerol & cholesterol standards for 5–15 minutes, and
absorbance read at 500 nm. Hepatic lipid levels were normalized to total protein
(BCA assay).
Total RNA was isolated from liver (50 mg) with Trizol Reagent (Invitrogen)
after homogenization with ZrOB05 beads (Next Advance). cDNA was synthesized
with 1 mg RNA using iScript cDNA Synthesis kit (Bio-Rad Laboratories). The
relative mRNA expression was determined by real-time PCR using Taqman Fast
Advanced Mastermix (Invitrogen) with Taqman Gene Expression Assay and
calculated by the comparative CT method, DDCT. The following expression assays
were used: apoAI (ApoaI- mm00437568_g1), apoE (Apoe-Mm01307193_g1),
ATP-binding cassette transporter (Abca1- mm00442646_m1), LDL-receptor
(Ldlr, mm00440169_m1), liver X receptor-a (Lxra, mm00443451_m1), scavenger
receptor B1 (Scarb1, mm00450234_m1), and sterol regulatory element binding
Apolipoprotein D and HDL
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transcription factor 2 (Srebf2, mm01306292_m1), and beta-2-microglobin (b2m-
mm00437762_m1).
HDL turnover studies
apoD2/2 HDL was isolated from pooled mouse plasma after 12 weeks on a
Western diet by sequential ultracentrifugation (density, 1.063,d,1.21). HDL was
labeled with 3H-1,2,3-cholesteryl oleate (Perkin Elmer) as previously described
[20] and 250,000 to 1 million counts per minute of 3H-CE-HDL was injected into
the retro-orbital sinus of Western-fed mice under isofluroane anesthesia. Blood
was collected at 5 minutes and 1, 5, 10, 24, and 48 hours, and liver and feces at 48
hours. Plasma decay curves were generated by subtracting the initial 5 min.
injection point from each time point. The fractional catabolism was fitted to a
biexponential curve using the WinSAAM modeling program, and FCR (per hour)
was calculated from the normalized area under the fitted curve [20].
Statistical analysis
Data are reported as mean ¡ SD and statistical significance was analyzed by a
student’s t-test using the GraphPad 6.0 software; p,0.05 was considered
significant.
Results
We investigated the role of apoD on HDL metabolism in mice on a high fat/
cholesterol diet. Given that plasma expression of apoD increased 2-fold on a
Western diet (WD) compared to chow diet in WT mice (Fig. 1), we analyzed
plasma lipids in male and female C57BL/6 and apoD2/2 mice after 12 weeks on
WD diet. Following a WD, plasma HDL-C was significantly higher in both male
(61¡13-apoD2/2 vs. 52¡10-WT, p,0.001) and female apoD2/2 mice
(37¡11-apoD2/2 vs. 22¡2, p,0.001) compared to WT mice (Table 1). This
observation was not seen on a chow diet (data not shown). However, the
commonality in HDL-cholesterol levels diverged for other lipid parameters
between the sexes in apoD2/2 mice (Table 1). In female apoD2/2 mice, a
significant increase in total cholesterol (90¡10-WT vs. 140¡14- apoD2/2,
p,0.05) was observed due to changes in both HDL and non-HDL cholesterol
levels (LDL, VLDL). Both plasma esterified cholesterol (CE) and free cholesterol
(FC) were increased with the greatest change in CE (+42%). Finally, there were
substantial decreases in both circulating triglyceride and NEFAs in female
apoD2/2 compared to control mice. In contrast, in male apoD2/2 mice there
were no significant differences in other plasma lipid parameters except for a
decrease (0.6¡0.1-apoD2/2 vs. 0.7¡0.1-WT, p,0.05) in non-esterified fatty
acids (NEFAs). Thus, a WD dramatically impacted plasma lipids in female
apoD2/2 mice compared to males. In the context of these clear differences in
HDL-C lipids in apoD2/2 mice on an atherogenic diet, we conducted more
Apolipoprotein D and HDL
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detailed analyses of the effects of apoD deficiency on HDL content, size, and
proteins.
Fig. 1. Up-regulation of plasma apoD levels in Western-fed WT mice. Western blot and semi-quantitative
analyses of apoD levels in WT mice fed a 12-week chow and Western diets. Data is representative of both
sexes, n54–5 per group, mean¡SD, *p,0.05.
doi:10.1371/journal.pone.0115744.g001
Table 1. Lipid parameters in male and female WT and apoD2/2 mice after 12 weeks on a Western diet.
Lipid Parameters WT Female (n57–9) apoD2/2 Female (n57–9) WT Male (n59–12) apoD2/2 Male (n59–12)
Total cholesterol 90¡10 140¡14* 174¡30 178¡34
HDL -C 22¡2 37¡11** 52¡10 61¡13**
Non-HDL-C 65¡13 103¡17** 123¡35 116¡28
FC 34¡5 44¡9* 39¡6 42¡7
CE 54¡7 92¡13**** 135¡28 136¡30
Triglycerides 60¡10 43¡7** 81¡15 84¡9
Phospholipids 132¡17 145¡18 170¡30 160¡11
NEFA (mEq/L) 0.6¡0.1 0.4¡0.1* 0.7¡0.1 0.6¡0.1*
Body weight (g) 26¡3 27¡3 30¡5 34¡5
Non-HDL-C and cholesteryl esters (CE) are calculated values. Values represent the mean¡SD, *p,0.05, **p,0.001, and ****p,0.0001. NEFA, n54–12.
FC5 free cholesterol.
doi:10.1371/journal.pone.0115744.t001
Apolipoprotein D and HDL
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The lipid and apolipoprotein compositions of HDL were determined in
fractions isolated by size-exclusion chromatography (SEC). For female mice,
apoD deficiency increased total cholesterol in both LDL and HDL fractions as well
as FC in HDL particles (Fig. 2A). Semiquantitative apoAI levels from SEC-HDL
fractions (31–37) were similar for both female WT and apoD2/2 mice (Fig. 3A).
Also, plasma apoAI levels were unchanged (Fig. 3B). The effect of apoD deficiency
on lipoprotein properties in male mice was different from that of females. Size
exclusion of pooled plasma, showed that compared to male WT mice, male
apoD2/2 mice had increased apoE-enriched HDL, which was larger as assessed
by total cholesterol levels (Fig. 2B). The HDL fractions (30–40) were slightly
higher in total cholesterol, free cholesterol, and phospholipids in male apoD2/2
mice compared to WT (Fig. 2B). Levels of apoAI in the larger lipid-rich HDL
fractions (fractions 32–40) were lower in male apoD2/2 vs. WT mice (Fig. 3A).
Moreover, SEC fractions 24–28 from apoD2/2 mice were more apoE-rich (lane
2) but had reduced apoAI levels (lane 4) than the corresponding fractions from
WT mice (lanes 1&3) (Fig. 3C). Analysis of circulating plasma levels of apoAI
were not different in male apoD2/2 compared to WT mice (Fig. 3B). These data
suggest that apoD influences both the heterogeneity in protein and lipid content
of circulating HDL-C levels with an shift towards larger, lipid rich HDL in a sex-
dependent manner.
We next quantified particle sizes and lipoprotein subpopulation concentrations
by ion mobility. For both sexes, there was an increase in the concentration of HDL
particles of all sizes in apoD2/2 versus control mice, with the majority of
particles in smaller denser HDL3/2a. The greatest increase in concentration of HDL
was, however, in larger HDL2b particles in apoD2/2 mice (Table 2). The
amount of the smaller particles, HDL3 and HDL2a (76.5–105 A˚), were increased by
2% in female apoD2/2 mice, whereas, only a 23% increase was seen in male
apoD2/2 mice compared to WT mice. The larger HDL2b particles (105–145 A˚)
were increased 28% in female mice and 69% in male apoD2/2 mice. The greater
increase of large HDL particles in males correlates well with the increase in apoE-
HDL particles by size exclusion column analysis. Interestingly, there was also an
increase in LDL particles with sex-dependent changes in the quantity and particle
sizes in apoD2/2 mice (Table 2). LDL particle sizes and concentrations were
elevated ,2-fold for male apoD2/2 mice; however, in females there was only a
15% increase in total LDL particles, with the most profound change in very small
atherogenic LDL particles (LDL4a-b) compared to WT mice. Overall, most of the
circulating lipoproteins were HDL particles in apoD2/2 mice, which correlate
with the observed changes in circulating plasma and by size exclusion
chromatography analyses.
To explain the increases in both plasma HDL-C and HDL particle size in
apoD2/2 mice on a Western diet, the activities of HDL-modifying proteins such
as LCAT and PLTP were measured. LCAT activity was unchanged in both sexes of
apoD2/2 mice compared to control mice (Fig. 4A). In contrast, there was a
significant but small (+10%) increase in PLTP activity in male apoD2/2 mice,
Apolipoprotein D and HDL
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with no differences in females (Fig. 4B). The difference in PLTP activity may
partially explain the changes in HDL particle sizes in male apoD 2/2 mice.
Hepatic lipid levels and gene and protein expression were assessed to uncover a
possible metabolic relationship between apoD and HDL-cholesterol levels. There
were no differences found in hepatic cholesterol and triglyceride levels between
control and apoD2/2 mice after the 12-week atherogenic diet (Fig. 5A–B).
Moreover, we considered the differential expression of genes involved in HDL
biogenesis and remodeling. We found no differences in the relative expression of
cholesterol transcription factor genes, sterol-regulatory element binding protein-2
(SREBF-2) and liver X receptor a (LXRa) in male mice, but in female apoD2/2
Fig. 2. ApoE-HDL enrichment and lipids content changes in HDL particles. Size exclusion chromatography lipid profiles (total cholesterol, free
cholesterol, phospholipids) of pooled plasma from A) female and B) male WT and apoD2/2 mice after 12 weeks on a Western diet.
doi:10.1371/journal.pone.0115744.g002
Apolipoprotein D and HDL
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Fig. 3. No change in plasma apoAI, but changes in apolipoproteins content in HDL-size exclusion chromatography fractions. A) Western blot
analysis of apoAI levels from the SEC-HDL fractions. B) Semi-quantitative analysis of plasma apoAI levels. C) SimpleStain and Western blotting for
apolipoprotein levels of pooled SEC-HDL fractions (10–20 mg).
doi:10.1371/journal.pone.0115744.g003
Apolipoprotein D and HDL
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mice there was a 1.5-fold increase in SREBF-2 (Fig. 5C). Furthermore, similar
expression levels of apoAI and apoE were found in all mice (Fig. 5C). Finally,
genes involved in hepatic HDL catabolism or synthesis, i.e., SCARB1, LDLR, and
ABCA1, were analyzed; only a ,1.5- difference in LDLR expression was observed
for both sexes in apoD2/2 mice (Fig. 4C). Analysis of liver protein expression of
both LDLR and SR-BI receptors showed the opposite effect than the mRNA
expression in female apoD2/2 mice (Fig. 5D). Both plasma membrane receptors
were significantly down-regulated between 15–54% (SR-BI: 1.3¡0.1-apoD2/2
vs. 1.5¡0.2-WT, p,0.05; and LDLR: 0.6¡0.3-apoD2/2 vs. 1.3¡0.2-WT,
p,0.005) in female apoD2/2 mice. There were no changes in the protein
expression of both these receptors in male mice (SR-BI: 1.8¡0.1-apoD2/2 vs.
Table 2. Lipoprotein particle size and concentrations (nmol/L) analyzed by IM methodology from pooled plasma of WT and apoD2/2 mice fed a Western
diet for 12 weeks.
Lipoprotein size fractions Female Male
WT apoD2/2 WT apoD2/2
Total HDL 11241 12488 4668 6416
Large 2b 3832 4897 1474 2493
Small 2a+b 7409 7591 3194 3923
Total LDL 37.21 43.32 39.68 84.12
Large 1 6.91 5.37 6.57 12.83
Medium 2a 3.12 3.56 4.25 9.57
Small 3a 6.03 5.81 6.02 14.21
Small 3b 3.05 4.04 3.89 9.00
Very small 4a 4.83 6.99 7.24 16.78
Very small 4b 8.99 13.48 11.71 21.73
Total VLDL 7.01 6.56 20.32 20.92
Large 0.54 0.66 7.89 6.62
Medium 2.53 2.67 7.88 8.21
Small 3.94 3.23 4.55 6.09
doi:10.1371/journal.pone.0115744.t002
Fig. 4. Increased PLTP activity. A) Plasma LCAT and B) PLTP activities from female and male WT and apoD2/2 mice on a Western diet for 12 weeks.
n57–14, values are mean¡SD, *p,0.05.
doi:10.1371/journal.pone.0115744.g004
Apolipoprotein D and HDL
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1.8¡0.2-WT; and LDLR: 1.6¡0.1-apoD2/2 vs. 1.4¡0.1-WT) (Fig. 5D). These
findings indicate that the increase in plasma LDL-C and HDL-C in female
apoD2/2 mice could be attributed to a decrease in hepatic receptor protein
Fig. 5. Decrease in the relative protein expression of SRBI and LDLR in female apoD2/2 mice but opposite pattern for mRNA expression. Liver
levels of A) Cholesterol and B) Triglyceride C) Relative expression of genes and D) Protein expression levels of LDLR and SRBI after 12 weeks on a
Western diet. n55–7 per group, mean¡SD, *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0115744.g005
Apolipoprotein D and HDL
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expression, and that other HDL-associated proteins may have led to the
accumulation of apoE-enriched HDL in the plasma of male apoD2/2 mice.
To determine the metabolic basis for an increase in plasma HDL levels, we
investigated the catabolism of apoD2/2 3H-CE-HDL in mice. No substantial
differences in HDL turnover or sterol tissue levels were observed in male mice
(Fig. 6). In contrast, there was a 36% decrease in the HDL-CE FCR in female
apoD2/2 mice in comparison to WT mice (Fig. 6A, 0.082¡0.014 vs.
0.061¡0.014 pools/h, p,0.05). However, there were no differences observed in
hepatic 3H-cholesterol counts or fecal extractions of 3H-cholesterol or bile acids in
both sexes (Fig. 6B–C). Thus, down-regulation of the HDL receptor or the
protein content of apoD2/2HDL particles may explain the differences in HDL
catabolism and the increase in plasma HDL-levels in female apoD2/2 mice.
Fig. 6. A decrease in 3H-CE HDL fractional catabolic rate in female apoD2/2mice only. Mice were fed a Western diet for 12 weeks and 3H-cholesteryl
oleate-labeled apoD2/2HDL was injected. A) Changes in plasma 3H-CE-HDL and calculated fractional catabolic rate (FCR), B) 3H-cholesterol (% of
injected dose) in the liver, C) 3H-sterol and bile acids (% of injected dose) in feces. The data represent n54–6 per group, mean¡SD, * indicates statistical
significant, p,0.05.
doi:10.1371/journal.pone.0115744.g006
Apolipoprotein D and HDL
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Discussion
This study investigated apoD as a candidate regulator of plasma HDL-C
metabolism. ApoD occurs predominantly on HDL and several studies suggest that
plasma apoD levels are associated with those of HDL or apoAI levels [12, 13, 14].
This is the first study to provide evidence that apoD deficiency modulates plasma
HDL-C and LDL-C levels. We observed a profound increase in circulating plasma
HDL-cholesterol levels and particle size in the apoD2/2 mice on an atherogenic
diet. These observations were confirmed by size-exclusion chromatography, as
well as lipoprotein-lipid and -protein analyses. PLTP but not LCAT activity was
modestly changed by apoD deficiency in male apoD2/2mice only. Despite being
,5% of HDL-protein in WT mice, apoD deficiency altered the distribution of the
major HDL protein and HDL particle size, which were associated with higher
circulating plasma HDL-C levels [21]. More importantly, in female apoD2/2
mice there was substantial decrease in plasma 3H-CE-HDL metabolism, which
coincided with a decrease in the expression of the hepatic HDL receptor, SR-BI.
These data suggest that reduction of plasma apoD levels plays a role in plasma
cholesterol homeostasis.
The reduction in SR-BI protein levels may underlie the reduced FCR for HDL
cholesteryl esters and thus cause elevated HDL-C levels in female vs. male
apoD2/2 mice. SR-BI is the key regulator of HDL-C plasma in the liver, and it
mediates the selective uptake of CE from circulating HDL, leading to a reduction
in HDL particle size [22]. Hepatic SR-BI deficient or SR-BI knockout mice have
significantly elevated plasma HDL-C levels while overexpression of SR-BI has the
opposite effect [23–27]. Furthermore, the plasma HDL phenotype in female
apoD2/2 mice resembles that of SR-BI2/2 mice with increased plasma
HDL-cholesterol and particle size with no changes in plasma apoA1 levels [23].
ApoD may be directly involved in regulation of SR-BI levels as SR-BI2/2:
apoE2/2 double knockout mice, a mouse model of coronary heart disease
(CHD), had significantly higher apoD mRNA expression levels [28]. Our data
show that apoD deficiency produces modest, but significant decreases in hepatic
SR-BI levels in female apoD2/2mice, which could be one mechanism for a lower
HDL-CE turnover rate and higher HDL plasma levels.
ApoD deficiency also modifies plasma cholesterol homeostasis via the
regulation of LDL-cholesterol. In humans, apoD occurs mainly on HDL; only 5%
of apoD occurs in human LDL and VLDL particles [29]. Quantitative trait loci
analysis suggested that chromosome 3, specifically the apoD locus, may influence
the plasma concentration of small, dense LDL-cholesterol [30]. A possible
mechanism for the observed changes in LDLR expression and plasma LDL-C
levels is post-transcriptional regulation since the mRNA levels of the LDLR gene
were increased, but protein expression was decreased. The LDLR is regulated on a
post-translational level, particularly by proprotein convertase subtilisin/kexin type
9 (PCSK9) and inducible degrader of the low-density lipoprotein receptor
(IDOL). PCSK9 affects LDLR stability and trafficking by promoting its
degradation by lysosomes, whereas IDOL ubiquitinates LDLR for proteasomal
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degradation [31–33]. Additional studies are needed to investigate hepatic Srebps,
PCSK9, or IDOL pathways to explain the increase in LDL-C levels.
The mechanistic regulation of plasma HDL-C in male apoD2/2 mice is
unclear. Male apoD2/2 mice showed no difference in CE-HDL catabolism,
despite an increase in PLTP activity and apoE-enriched HDL particles. The
increased PLTP activity in the male mice could be involved in the appearance of a
minor population of spherical apoE-enriched HDL particles. Future studies will
be required to determine the mechanism for changes in HDL-C levels in male
apoD2/2 mice.
Conclusions
This study demonstrated that apoD may directly or indirectly modulate the levels,
size, and apolipoprotein content of HDL in a sex-dependent manner. Thus, our
new findings suggest that in female mice the absence of apoD may promote a pro-
atherogenic phenotype via its regulation of circulating HDL-C concentrations,
reflecting SR-BI deficiency, and the increase in small-dense LDL-C levels and
particles. These data may support the notion that expression of apoD is protective
under different stress conditions and especially in different animal models of CHD
such as ischemia/reperfusion-induced myocardial infarction or diet-induced
atherosclerosis [25].
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